Toggle Main Menu Toggle Search

Open Access padlockePrints

Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council

Lookup NU author(s): Dr James Roberts

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Purpose: to test the equivalence of three versus four cycles of bleomycin, etoposide, and cisplatin (BEP) and of the 5-day schedule versus 3 days per cycle in good-prognosis germ cell cancer. Patients and Methods: The study was designed as a 2 x 2 factorial trial. The aim was to rule out a 5% decrease in the 2-year progression-free survival (PFS) rate. The study included the assessment of patient quality of life. A cycle of BEP consisted of etoposide 500 mg/m(2), administered at either 100 mg/m(2) days 1 through 5 or 165 mg/m2 days 1 through 3, cisplatin 100 mg/m2, administered at either 20 mg/m(2) days 1 through 5 or 50 mg/m(2) days 1 and 2. Bleomycin 30 mg was administered on days 1, 8, and 15 during cycles 1 through 3. The randomization procedure allowed some investigators to participate only in the comparison of three versus four cycles. Results: From March 1995 until April 1998, 812 patients were randomly assigned to receive three or four cycles: of these, 681 were also randomly assigned to the 5-day or the 3-day schedule. Histology, marker values, and disease extent are well balanced in the treatment arms of the two comparisons. The projected 2-year PFS is 90.4% on three cycles and 89.4% on four cycles. The difference in PFS between three and four cycles is -1.0% (80% confidence limit [CL], -3.8%, +1.8%). Equivalence for three versus four cycles is chimed because both the upper and lower bounds of the 80% CL are less than 5%. In the 5- versus 3-day comparison, the projected 2-year PFS is 88.8% and 89.7%, respectively difference, -0.9%, (80% CL, -4.1%, +2.2%). Hence, equivalence is claimed in this comparison also. Frequencies of hematologic and nonhematologic toxicities were essentially similar. Quality of life was maintained better in patients receiving three cycles; no differences were defected between 3 and 5 days of treatment. Conclusion: We conclude that three cycles of BEP, with etoposide at 500 mg/m2, is sufficient therapy in good-prognosis germ cell cancer and that the administration of the chemotherapy in 3 days has no detrimental effect on the effectiveness of the BEP regimen. (C) 2001 by American Society of Clinical Oncology.


Publication metadata

Author(s): de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Fossa SD, Cook P, de Prijck L, Stenning S, Collette L

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Oncology

Year: 2001

Volume: 19

Issue: 6

Pages: 1629-1640

ISSN (print): 0732-183X

ISSN (electronic): 1527-7755

Publisher: American Society of Clinical Oncology


Funding

Funder referenceFunder name
5U10 CA11488-24NCI NIH HHS
5U10 CA11488-29NCI NIH HHS
5U10 CA 11488-27NCI NIH HHS
5U10 CA11488-25NCI NIH HHS
5U10 CA11488-26NCI NIH HHS
5U10 CA11488-28NCI NIH HHS

Share